Concepedia

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell, Scott H. Donaldson, Kristin A. Riekert, Gregory S. Sawicki, Katherine Odem‐Davis, J. Young, Daniel Rosenbluth, Jennifer L. Taylor‐Cousar,

The Lancet Respiratory Medicine · 2022 · 126 citations · 36 references

DOIFull text

Open access

Concepts

References

36

Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations

Philip H. Quanjer, Sanja Stanojevic, Tim Cole et al. · European Respiratory Journal · 2012 · 5.9K citations · Full text

, , +12

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text

, , +16

Effect of Aerosolized Recombinant Human DNase on Exacerbations of Respiratory Symptoms and on Pulmonary Function in Patients with Cystic Fibrosis

Henry J. Fuchs, Drucy Borowitz, David Høyrup Christiansen et al. · New England Journal of Medicine · 1994 · 1.5K citations · Full text

, , +14

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

, , +14

Cystic Fibrosis Pulmonary Guidelines

Patrick A. Flume, Brian O’Sullivan, Karen A. Robinson et al. · American Journal of Respiratory and Critical Care Medicine · 2007 · 1K citations

, , +9